Skip to main content

Advertisement

Table 4 Association of baseline serum adipokine levels and rapid radiographic disease progression defined as an increase of ≥ 5 units in total SHS between inclusion and 1 year (total ∆SHS ≥5)

From: Serum level of adiponectin is a surrogate independent biomarker of radiographic disease progression in early rheumatoid arthritis: results from the ESPOIR cohort

  Univariate model Model 1 “Base” Model 2 “metabolic” Model 3 “metabolic + RA” Model 4 “metabolic + RA + steroid”
OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P
Adiponectin ∆SHS ≥ 5 1.47 (0.98-2.20) 0.06 1.7 (1.11-2.61) 0.02 1.85 (1.16-2.94) 0.01 2.0 (1.14-3.52) 0.02 2.0 (1.14-3.52) 0.02
Leptin ∆SHS ≥ 5 0.73 (0.54-0.97) 0.03 0.75 (0.55-1.04) 0.09 0.98 (0.61-1.56) 0.92 0.97 (0.55-1.68) 0.90 0.97 (0.56-1.68) 0.90
Visfatin/NAMPT ∆SHS ≥ 5 1.14 (0.83 1.56) 0.41 1.12 (0.82-1.54) 0.48 1.11 (0.79-1.55) 0.56 0.96 (0.64-1.44) 0.85 0.96 (0.64-1.44) 0.85
  1. OR, odds ratio; 95% CI, 95% confidence interval.
  2. Multivariate models:
  3. Model 1 (“base”): sex + age.
  4. Model 2 (“metabolic”): model 1 + BMI + HOMA-IR index.
  5. Model 3 (“metabolic + RA”): model 2 + CRP level + DAS28-ESR value + HAQ score + RF status + anti-CCP antibody status + presence of radiographic changes at inclusion.
  6. Model 4 (“metabolic + RA + steroid”): model 3 + steroid prescription at inclusion.
  7. The following variables were log-transformed: CRP level, HAQ score, serum adipokine levels. Bold P values are significant.